iGeneTech Bioscience Co., Ltd.
EN

IGT: Precise Traceability, Early Detection of Chlamydia psittaci

Table of Content [Hide]

    Chlamydia psittaci (Cp) is a zoonotic pathogen that is primarily transmitted among birds and can infect humans, causing community-acquired pneumonia (CAP). Its post-infection clinical manifestations are diverse, ranging from mild nonspecific symptoms to severe pneumonia and even multiple organ dysfunction, with relatively high rates of misdiagnosis and missed diagnosis.

    鹦鹉热2.png 

    Figure 1. Life Cycle of Chlamydia psittaci (cited from Wikipedia)

     

    IGT Solution
    Diagnosing Chlamydia psittaci is challenging. Traditional methods such as the isolation and culture method have strict requirements on conditions and are time-consuming; serological testing is susceptible to cross-reactions, resulting in insufficient diagnostic specificity. These limitations make rapid and accurate diagnostic methods an urgent issue to be addressed.

    肺支2.jpg 

    Figure 2. Design Concept of IGT's Pathogen Whole-Genome Capture Probes

     

    IGT has developed a Chlamydia psittaci full-length capture kit based on its independently owned TargetSeq® liquid probe hybridization capture technology and a unique microbial probe design scheme. Using the full-length sequence of Chlamydia psittaci from the NCBI database as the reference sequence, a total of 166,256 probes were designed. Through rigorous screening and optimization, these probes ensure comprehensive coverage and efficient capture of the genomic information of the target pathogen.

     

    Strong Data Support
    Experimental data show that IGT's Chlamydia psittaci panel performs excellently in key indicators such as total reads mapping rate, coverage, and uniformity, effectively improving the accuracy and reliability of detection.

     

    鹦鹉热1.png

    Figure 3. Results of total reads mapping rate, coverage, and 20× coverage rate of test samples

     鹦鹉热3.png 

    Figure 4. Display of Measured Coverage

     

    Related Products
    As of July 2025, IGT has developed over 30 single-pathogen capture probe kits, covering various pathogens under routine monitoring and key concerns of disease control systems.

    Whole-genome capture kits are available, including full-process reagents for sample extraction, library preparation, and hybrid capture, suitable for multiple high-throughput sequencing platforms.

    Meanwhile, customized probe design and detection protocols can be provided according to customer needs to meet special research requirements.

     


    References